DENVER — Trudhesa nasal spray provided pain relief for up to three consecutive migraine attacks in an open-label, 52-week phase 3 trial, researchers said at the American Headache Society annual scientific meeting.
Trudhesa (dihydroergotamine mesylate, Impel Pharmaceuticals) uses Precision Olfactory Delivery technology for rapid absorption and bioavailability of the drug, the company said in a press release. Nasal delivery allows the therapeutic to bypass the gut and reduces potential absorption issues, while offering consistent symptom relief without nausea.
“These data suggest that